These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 17976085

  • 1. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [Abstract] [Full Text] [Related]

  • 2. Attainment of the Japanese Society for Dialysis Therapy guidelines for the management of secondary hyperparathyroidism in chronic hemodialysis patients in our clinic.
    Sato Y, Eriguchi R, Umakoshi J, Kato M.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S48-53. PubMed ID: 17976086
    [Abstract] [Full Text] [Related]

  • 3. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result.
    Kimata N, Miwa N, Otsubo S, Iwasaki T, Yabuki Y, Miyabe K, Asamiya Y, Sato K, Sugi O, Ikebe N, Kiuchi K, Mineshima M, Akiba T.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S62-6. PubMed ID: 17976088
    [Abstract] [Full Text] [Related]

  • 4. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H, Fukagawa M, KRN1493 Study Group.
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [Abstract] [Full Text] [Related]

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S, Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2010 Aug 01; 14(4):424-31. PubMed ID: 20649764
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C, Multicentric group for the study of the phosphocalcic metabolism in the community of Valencia.
    J Nephrol; 2005 Aug 01; 18(6):739-48. PubMed ID: 16358233
    [Abstract] [Full Text] [Related]

  • 10. The need for better control of secondary hyperparathyroidism.
    Locatelli F.
    Nephrol Dial Transplant; 2004 Aug 01; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [Abstract] [Full Text] [Related]

  • 11. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C, González EA, Martin KJ.
    Ther Apher Dial; 2005 Feb 01; 9(1):4-8. PubMed ID: 15828898
    [Abstract] [Full Text] [Related]

  • 12. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Feb 01; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK.
    Am J Kidney Dis; 2008 Sep 01; 52(3):519-30. PubMed ID: 18514987
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N, Amor J, Cambil T, Salgueira M, Sánchez-Palencia R, Páez C, Gómez O, Palma A.
    Nefrologia; 2003 Sep 01; 23 Suppl 2():64-8. PubMed ID: 12778857
    [Abstract] [Full Text] [Related]

  • 17. [Secondary hyperparathyroidism in renal insufficiency. Prevention and therapy].
    Malluche HH, Ritz E.
    MMW Munch Med Wochenschr; 1976 Jan 30; 118(5):129-30. PubMed ID: 814442
    [No Abstract] [Full Text] [Related]

  • 18. [Secondary hyperparathyroidism: incidence, clinical presentations, treatment].
    Samokhvalova NA, Romanchishen AF, Gerasimchuk RP, Grinev KM, Zemchenkov AIu.
    Vestn Khir Im I I Grek; 2007 Jan 30; 166(5):78-81. PubMed ID: 18154100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Control of calcium and phosphate in hemodialysis patients].
    Eriguchi R, Takei S, Satou Y.
    Clin Calcium; 2005 Sep 30; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.